Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome

AUTOR(ES)

Griffin, John H.

FONTE

National Academy of Sciences

RESUMO

Idiopathic hypereosinophilic syndrome (HES) is a myeloproliferative disease of unknown etiology. Recently, it has been reported that imatinib mesylate (Gleevec), an inhibitor of Bcr-Abl kinase useful in the treatment of chronic myeloid leukemia, is also effective in treating HES; however, the molecular target of imatinib in HES is unknown. This report identifies a genetic rearrangement in the eosinophilic cell line EOL-1 that results in the expression of a fusion protein comprising an N-terminal region encoded by a gene of unknown function with the GenBank accession number NM_030917 and a C-terminal region derived from the intracellular domain of the platelet-derived growth factor receptor α (PDGFRα). The fusion gene was also detected in blood cells from two patients with HES. We propose naming NM_030917 Rhe for Rearranged in hypereosinophilia. Rhe-PDGFRα fusions result from an apparent interstitial deletion that links Rhe to exon 12 of PDGFRα on chromosome 4q12. The fusion kinase Rhe-PDGFRα is constitutively phosphorylated and supports IL-3-independent growth when expressed in BaF3 cells. Proliferation and viability of EOL-1 and BaF3 cells expressing Rhe-PDGFRα are ablated by the PDGFRα inhibitors imatinib, vatalanib, and THRX-165724.

Documentos Relacionados

• T cells in idiopathic hypereosinophilic syndrome.
• T cell lymphoid aggregates in idiopathic hypereosinophilic syndrome.
• Intracranial haemorrhages occurring in the idiopathic hypereosinophilic syndrome.
• Idiopathic hypereosinophilic syndrome with 20 years of diagnostic delay
• T cell lymphoid aggregates in bone marrow in idiopathic hypereosinophilic syndrome